LT3377484T - Dauginės sklerozės gydymo būdai, panaudojant pirimidino ir piridino junginius su btk inhibitoriniu aktyvumu - Google Patents
Dauginės sklerozės gydymo būdai, panaudojant pirimidino ir piridino junginius su btk inhibitoriniu aktyvumuInfo
- Publication number
- LT3377484T LT3377484T LTEPPCT/US2016/062154T LTUS2016062154T LT3377484T LT 3377484 T LT3377484 T LT 3377484T LT US2016062154 T LTUS2016062154 T LT US2016062154T LT 3377484 T LT3377484 T LT 3377484T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrimidine
- treatment
- multiple sclerosis
- inhibitory activity
- pyridine compounds
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256199P | 2015-11-17 | 2015-11-17 | |
| PCT/US2016/062154 WO2017087445A1 (en) | 2015-11-17 | 2016-11-16 | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3377484T true LT3377484T (lt) | 2023-12-27 |
Family
ID=57460611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/062154T LT3377484T (lt) | 2015-11-17 | 2016-11-16 | Dauginės sklerozės gydymo būdai, panaudojant pirimidino ir piridino junginius su btk inhibitoriniu aktyvumu |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10716788B2 (enExample) |
| EP (2) | EP4295910A3 (enExample) |
| JP (1) | JP6891173B2 (enExample) |
| KR (1) | KR102780243B1 (enExample) |
| CN (1) | CN108884076B (enExample) |
| AU (1) | AU2016357735B2 (enExample) |
| BR (1) | BR112018007517B1 (enExample) |
| CL (1) | CL2018001252A1 (enExample) |
| DK (1) | DK3377484T3 (enExample) |
| ES (1) | ES2964946T3 (enExample) |
| FI (1) | FI3377484T3 (enExample) |
| HR (1) | HRP20231547T1 (enExample) |
| HU (1) | HUE064244T2 (enExample) |
| IL (1) | IL258978B (enExample) |
| LT (1) | LT3377484T (enExample) |
| MX (1) | MX386146B (enExample) |
| MY (1) | MY199473A (enExample) |
| NZ (1) | NZ741294A (enExample) |
| PH (1) | PH12018500736A1 (enExample) |
| PL (1) | PL3377484T3 (enExample) |
| PT (1) | PT3377484T (enExample) |
| RS (1) | RS64908B1 (enExample) |
| SI (1) | SI3377484T1 (enExample) |
| UA (1) | UA123159C2 (enExample) |
| WO (1) | WO2017087445A1 (enExample) |
| ZA (1) | ZA201802348B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202510883A (zh) * | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| EP3810590A1 (en) * | 2018-06-19 | 2021-04-28 | Merck Patent GmbH | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CN112250666B (zh) * | 2020-10-09 | 2022-01-14 | 广东东阳光药业有限公司 | 取代的嘧啶类化合物及其用途 |
| JP2023551679A (ja) * | 2020-12-02 | 2023-12-12 | テリオス ファーマ， インコーポレイテッド | 眼科疾患を治療するための方法及び組成物 |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| US20260000669A1 (en) | 2022-06-24 | 2026-01-01 | Merck Patent Gmbh | Treatment regimen for autoimmune diseases and inflammatory diseases |
| WO2024099241A1 (zh) * | 2022-11-07 | 2024-05-16 | 天津征程医药科技有限公司 | 氘代的嘧啶衍生物以及包含该化合物的药物组合物 |
| WO2025096900A1 (en) * | 2023-11-03 | 2025-05-08 | Board Of Regents, The University Of Texas System | Synthetic network materials and methods of making and use thereof |
| US12414950B1 (en) * | 2024-05-21 | 2025-09-16 | Telios Pharma Inc. | Methods of treating indolent systemic mastocytosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| GB0512844D0 (en) * | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| MX2012002641A (es) | 2009-09-10 | 2012-03-14 | Hoffmann La Roche | Inhibidores de cinasa janus (jak). |
| KR101301533B1 (ko) | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
| US9073947B2 (en) * | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| US20150291554A1 (en) * | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
| WO2014093230A2 (en) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| WO2014163161A1 (ja) * | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3483167A1 (en) * | 2013-06-26 | 2019-05-15 | AbbVie Inc. | Primary carboxamides as btk inhibitors |
| JP6612751B2 (ja) * | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| KR20160060100A (ko) * | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| TW202510883A (zh) * | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
-
2016
- 2016-11-16 KR KR1020187014258A patent/KR102780243B1/ko active Active
- 2016-11-16 HU HUE16805251A patent/HUE064244T2/hu unknown
- 2016-11-16 HR HRP20231547TT patent/HRP20231547T1/hr unknown
- 2016-11-16 UA UAA201806687A patent/UA123159C2/uk unknown
- 2016-11-16 SI SI201631768T patent/SI3377484T1/sl unknown
- 2016-11-16 CN CN201680078780.9A patent/CN108884076B/zh active Active
- 2016-11-16 NZ NZ741294A patent/NZ741294A/en unknown
- 2016-11-16 BR BR112018007517-5A patent/BR112018007517B1/pt active IP Right Grant
- 2016-11-16 MX MX2018005463A patent/MX386146B/es unknown
- 2016-11-16 PT PT168052512T patent/PT3377484T/pt unknown
- 2016-11-16 PL PL16805251.2T patent/PL3377484T3/pl unknown
- 2016-11-16 MY MYPI2018701467A patent/MY199473A/en unknown
- 2016-11-16 EP EP23195454.6A patent/EP4295910A3/en active Pending
- 2016-11-16 AU AU2016357735A patent/AU2016357735B2/en active Active
- 2016-11-16 WO PCT/US2016/062154 patent/WO2017087445A1/en not_active Ceased
- 2016-11-16 RS RS20231155A patent/RS64908B1/sr unknown
- 2016-11-16 FI FIEP16805251.2T patent/FI3377484T3/fi active
- 2016-11-16 LT LTEPPCT/US2016/062154T patent/LT3377484T/lt unknown
- 2016-11-16 JP JP2018525702A patent/JP6891173B2/ja active Active
- 2016-11-16 EP EP16805251.2A patent/EP3377484B1/en active Active
- 2016-11-16 ES ES16805251T patent/ES2964946T3/es active Active
- 2016-11-16 US US15/352,657 patent/US10716788B2/en active Active
- 2016-11-16 DK DK16805251.2T patent/DK3377484T3/da active
-
2018
- 2018-04-03 PH PH12018500736A patent/PH12018500736A1/en unknown
- 2018-04-10 ZA ZA2018/02348A patent/ZA201802348B/en unknown
- 2018-04-26 IL IL258978A patent/IL258978B/en active IP Right Grant
- 2018-05-09 CL CL2018001252A patent/CL2018001252A1/es unknown
-
2020
- 2020-06-08 US US16/946,145 patent/US20200316068A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE064244T2 (hu) | Módszerek szklerózis multiplex kezelésére BTK gátló aktivitású pirimidin- és piridin-származékokkal | |
| DK3716976T3 (da) | Fremgangsmåder til behandling med cyp3a4-substratlægemidler | |
| DK3240773T3 (da) | Picolinamidforbindelser med fungicid aktivitet | |
| GB2549545B (en) | Forensic analysis of computing activity | |
| LT3559009T (lt) | Kompozicijos ir būdai, skirti arginazės aktyvumo slopinimui | |
| IL257327B (en) | Nicotinamide mononucleotide derivatives and their uses | |
| LT4129407T (lt) | Arilo, heteroarilo ir heterocikliniai junginiai, skirti komplemento nulemtiems sutrikimams gydyti | |
| EP3160475C0 (en) | NUCLEOSIDES AND SUBSTITUTED NUCLEOTIDES FOR TREATING INFECTIONS DUE TO FILOVIRIDAE | |
| LT3429596T (lt) | Cikliniai dinukleotidų junginiai ir panaudojimo būdai | |
| SG11201802927VA (en) | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity | |
| LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
| MA41213A (fr) | Nucléosides substitués, nucléotides et analogues de ceux-ci | |
| MA41441A (fr) | Nucléosides substitués, nucléotides et analogues de ceux-ci | |
| PL3212174T3 (pl) | Sposoby leczenia zakażeń wirusem filoviridae | |
| DK3292145T3 (da) | Fc-mutanter med modificeret funktionel aktivitet | |
| EP3137606A4 (en) | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | |
| EP3091976C0 (en) | PYRIDONE AND PIRFENIDONE ANALOGUE COMPOUNDS IN AEROSOL, AND THEIR USES | |
| EP3357922A4 (en) | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND USE THEREOF | |
| LT3128005T (lt) | Sirp-alfa varianto konstruktai, ir jų panaudojimas | |
| EP3285644C0 (en) | DETECTION OF ACTIVITY IN PERIPHERAL NERVE | |
| FI20155290A7 (fi) | Pyrolyysihöyryjen katalyyttinen jalostus | |
| LT3268480T (lt) | Priemonės ir būdai, skirti panaudoti ląstelių dalijimosi lokusus ląstelių proliferacijos kontroliavimui | |
| DK3167052T3 (da) | P450-bm3-varianter med forbedret aktivitet | |
| LT3191514T (lt) | Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas |